Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com

StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a buy rating to a hold rating in a research note released on Thursday.

Separately, HC Wainwright restated a neutral rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP stock opened at $2.48 on Thursday. The firm’s 50-day simple moving average is $2.41 and its two-hundred day simple moving average is $2.45. Oramed Pharmaceuticals has a 52 week low of $1.67 and a 52 week high of $3.67. The firm has a market cap of $101.11 million, a price-to-earnings ratio of 9.54 and a beta of 1.77.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.01 by $0.21. Analysts forecast that Oramed Pharmaceuticals will post 0.24 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ORMP. Murchinson Ltd. raised its holdings in Oramed Pharmaceuticals by 31.4% in the 1st quarter. Murchinson Ltd. now owns 1,379,495 shares of the biotechnology company’s stock worth $4,028,000 after purchasing an additional 329,495 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Oramed Pharmaceuticals in the 1st quarter worth approximately $68,000. Dimensional Fund Advisors LP raised its stake in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after acquiring an additional 10,774 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after buying an additional 108,700 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Oramed Pharmaceuticals in the second quarter worth $40,000. 12.73% of the stock is currently owned by institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.